Invion Ltd.ASX: IVX

Invion Receives $0.5m R&D Tax Incentive Rebate

· Issued by Invion Ltd. via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

The funding is part of Invion's strategy to finance its clinical pipeline, including upcoming trials for skin cancer and anogenital indications. The announcement was approved by Invion’s Board of Directors and highlights the importance of non-dilutive funding for the company's research efforts.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX ANNOUNCEMENT INVION RECEIVES >$0.5M R&D TAX INCENTIVE REBATE MELBOURNE (AUSTRALIA) 19 November 2026: Invion Limited (ASX: IVX) ("Invion" or the "Company"), a clinical-stage life sciences company developing its next-generation photodynamic therapy platform (NGPDT) called Photosoft™, is pleased...

Invion Ltd. on 6ix

Earlier from Invion

All Invion news releases